A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome

@article{Adhikari2018APP,
  title={A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome},
  author={Narayan Adhikari and Ahitagni Biswas and Ajay Gogia and Ranjit Kumar Sahoo and Ajay Garg and Ashima Nehra and Mehar Chand Sharma and Suman Bhasker and Manmohan Singh and Vishnubhatla Sreenivas and Rohan Chawla and Garima Joshi and Lalit Kumar and Subhash Chander},
  journal={Journal of Neuro-Oncology},
  year={2018},
  volume={139},
  pages={153-166}
}
BackgroundThe treatment of primary CNS lymphoma (PCNSL) comprises high dose methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy (WBRT), the major drawback of which is long term neurotoxicity. We intended to assess the feasibility of response adapted WBRT in PCNSL in the Indian setting.MethodsWe screened 32 patients and enrolled 22 eligible patients with PCNSL from 2015 to 2017 in a prospective phase II trial. The patients underwent five 2-weekly cycles of induction… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Effect of rituximab in primary central nervous system lymphoma: results of the randomized phase III HOVON 105/ALLG NHL 24 Study

J Bromberg, S Issa, K Bukanina
  • Blood
  • 2017
VIEW 1 EXCERPT

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 2 EXCERPTS

Primary brain tumours in adults

PG Morris, LE Abrey
  • Lancet
  • 2012